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Background: Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-associated liver disease with potentially
deleterious consequences for the fetus, particularly when maternal serum bile-acid concentration >40 μM. However, the
etiology and pathogenesis of ICP remain elusive. To reveal the underlying molecular mechanisms for the association of
maternal serum bile-acid level and fetal outcome in ICP patients, DNA microarray was applied to characterize the
whole-genome expression profiles of placentas from healthy women and women diagnosed with ICP.
Methods: Thirty pregnant women recruited in this study were categorized evenly into three groups: healthy group; mild
ICP, with serum bile-acid concentration ranging from 10–40 μM; and severe ICP, with bile-acid concentration >40 μM.
Gene Ontology analysis in combination with construction of gene-interaction and gene co-expression networks were
applied to identify the core regulatory genes associated with ICP pathogenesis, which were further validated by
quantitative real-time PCR and histological staining.
Results: The core regulatory genes were mainly involved in immune response, VEGF signaling pathway and
G-protein-coupled receptor signaling, implying essential roles of immune response, vasculogenesis and angiogenesis in
ICP pathogenesis. This implication was supported by the observed aggregated immune-cell infiltration and deficient
blood vessel formation in ICP placentas.
Conclusions: Our study provides a system-level insight into the placental gene-expression profiles of women with mild
or severe ICP, and reveals multiple molecular pathways in immune response and blood vessel formation that might
contribute to ICP pathogenesis.
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Intrahepatic cholestasis of pregnancy (ICP) is the most fre-
quent liver disease arising in the second or third trimester
of pregnancy. Clinically, ICP is characterized by maternal
pruritus, deranged liver function, elevated serum level of
bile acids, and spontaneous relief of signs and symptoms* Correspondence: tduan@yahoo.com; jfchen@sibcb.ac.cn
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unless otherwise stated.in the mother within 2–3 weeks after delivery [1,2]. The
prevalence of this disease has been found to be variable,
ranging from 0.1-4.0% [1,3]. In contrast to the benign ef-
fects on the mother, ICP has severe consequences for the
fetus: it is associated with an increased risk of fetal pre-
term delivery (19–60% of ICP cases), fetal distress (22–
41%), and fetal loss (0.4–1.6%) [4]. However, the etiology
and pathogenesis of ICP remain elusive.
An indispensible criterion for ICP is elevation in the
serum levels of bile acids, which is considered to be the
most appropriate laboratory parameter for diagnosis of
the condition [5-7]. During a healthy pregnancy, bile acidsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion and exported into the maternal circulation across a
steep transplacental gradient [8,9]. In cases of maternal
cholestasis, however, the serum levels of bile acids are ele-
vated in both maternal and fetal serum, resulting in a re-
versal in the transplacental gradient and consequently
impairing the export of bile acids from the fetus into the
maternal circulation [10,11]. Rates of fetal complication
are positively correlated with the total level of bile acids in
maternal serum of ICP patients: the probability of fetal
complications increases by 1–2% for each additional 1 μM
of bile acids, whereas the probability of these events did
not increase until bile-acid levels >40 μM [6]. Although
the association of maternal serum bile-acid level and fetal
outcome has been reported, the underlying mechanisms
remain unknown.
The placenta connects the developing fetus to the uterine
wall and allows nutrient uptake, waste elimination, and gas
exchange between the fetal and maternal blood supplies.
The placenta is believed to play a critical role in ICP patho-
genesis [12]. Previous studies using human placental tissues
or a rodent model of ICP have revealed several morpho-
logical abnormalities in ICP placentas, including focally
thickened amniotic basement membranes, chorionic villi
that are small for gestational age, crowding and congestion
of the villi, and an increased number of syncytial knots
[12,13]. In addition, increased apoptosis, oxidative stress,
and hypoxia have been observed in rat ICP placentas [12].
Thus, in this study, to reveal the molecular mechanisms for
the association of maternal serum bile-acid level and fetal
outcome in ICP patients, we categorized the ICP pa-
tients into two groups (mild ICP, with serum bile-acid
concentration ranging from 10–40 μM; severe ICP, with
bile-acid concentration >40 μM) and used DNA micro-
array to characterize the whole-genome expression pro-
files of placentas. Our system-level analyses of placental
gene-expression profiles of ICP, coupled with validation
of predicted tissue phenotypes, reveal multiple molecu-
lar pathways in immune response and blood vessel for-
mation that might contribute to ICP pathogenesis.
Methods
Ethics statement
This study was approved by the Research Committee for
Human Subjects, Shanghai Tongji University School of
Medicine. All participants provided their written informed
consent to participate in this study.
Patients and tissues
Thirty pregnant women recruited in this study were cat-
egorized into three groups (ten pregnancies in each
group) according to the serum bile acid level at gesta-
tional age of 32 weeks: healthy group with serum bile
acid concentration < 10 μM; mild ICP, with serum bileacid concentration ranging from 10–40 μM; and severe
ICP, with bile acid concentration >40 μM (Figure 1A). ICP
was diagnosed with the following symptoms: 1) presence
of classical pruritus with no rash and quick disappearance
after delivery; 2) raised maternal serum bile-acid concen-
tration (>10 μM); 3) absence of itching skin disease; and 4)
absence of any other causes of liver dysfunction, including
preeclampsia; hemolysis, elevated liver enzymes and low
platelets (HELLP) syndrome; acute fatty liver of preg-
nancy; primary biliary cirrhosis; viral hepatitis; and any
ultrasound abnormality. All of the ICP patients were not
treated with UDCA under their consents. Exclusion cri-
teria for recruitment of healthy pregnant women were
similar to that for ICP cases.
To avoid artefact from effects of labor, only placental
samples obtained from women who had not undergone
labor were selected. All samples were collected immedi-
ately after Caesarean sections, cut near the center zone
of maternal surface villous lobule after deciduas and
amnionic membranes were removed, and then rinsed
with saline to remove maternal blood.
Total serum bile acids analysis
Fasting Serum samples were taken from women and
measured twice every week since the gestational age of
32 weeks until caesarean section. Total bile acids were
assessed by using an enzymatic method (Kit No Bl 3863,
Randox Laboratoires Ltd, United Kingdom) on a Hitachi
7180 biochemistry analyzer (Hitachi, Tokyo, Japan).
RNA preparation
Freshly isolated placental tissues were divided and dissected
separately on ice-cooled RNase-free surfaces. Each sample
was placed into an individual tube before addition of 1 mL
of TRIzol reagent (Invitrogen), followed by homogenization
with a Polytron mixer (Kinematica). Total RNA was ex-
tracted according to manufacturer’s instructions (Invitro-
gen). For DNA microarray, ten pregnant women in each
group were randomly divided into two sub-groups and
equal amounts of RNA from five individuals in each sub-
group were pooled for one array to reduce the variations
among different individuals [14,15].
DNA microarray and hybridization
Agilent Human 4 × 44 K Gene Expression Arrays, which
target 27 958 Entrez Gene RNAs, were employed in this
study. Sequences were compiled from a broad survey of
sources and were subsequently verified and optimized by
alignment to the assembled human genome. Coupled with
Agilent’s probe selection and robust validation processes,
this design delivers increased data quality and less redun-
dancy in gene coverage.
Sample labeling and array hybridization were per-
formed according to the Agilent One-Color Microarray-
Figure 1 Hierarchical clustering of differentially expressed genes in placentas from healthy pregnancies and women with ICP. (A)
Clinical features of healthy women and women with mild or severe ICP. 10 pregnant women were recruited for each group, and data are shown
as mean ± s.d. (n = 10). (B) Hierarchical clustering of genes whose expression was altered by more than 1.5-fold in ICP placentas comparing to
those in healthy placentas. Red and green represent individual genes that were differentially up-regulated or down-regulated, respectively.
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nology). Briefly, total RNA from each sample was
linearly amplified and labeled with Cy3-UTP. The la-
beled cRNAs were purified using the RNeasy Mini Kit
(QIAGEN). The concentration and specific activity of
the labeled cRNAs (pmol Cy3/μg cRNA) were measured
using a NanoDrop ND-1000. One microgram of each la-
beled cRNA was fragmented by addition of 11 μl 10×
Blocking Agent and 2.2 μl 25× Fragmentation Bufferfollowed by heating at 60°C for 30 min. Finally, 55 μl 2×
GE Hybridization buffer was added to dilute the labeled
cRNA. One hundred microliters of hybridization solution
was dispensed into the gasket slide, which was assembled
with the gene expression microarray slide, followed by in-
cubation for 17 hours at 65°C in an Agilent Hybridization
Oven. The hybridized arrays were washed, fixed, and
scanned with the Agilent DNA Microarray Scanner (part
number G2505B).
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Agilent Feature Extraction software (version 11.0.1.1)
was used to analyze acquired array images. Quantile
normalization and subsequent data processing were
performed using the GeneSpring GX v12.0 software
package. Genes that had flags in at least two out of six
arrays were chosen for further analysis. Detailed gene
expression data are available at the GEO website under
accession number GSE46157.
To sort the differentially expressed genes in mild ICP and
severe ICP compared with healthy pregnancy, microarray
data were analyzed by using linear models and empirical
Bayes method, which is considered to be able to generate a
reliable statistical inference when the number of arrays is
small [16,17]. This method is similar to a standard t test for
each probe except that the SES are moderated across genes
to get more stable results, which prevents a gene with a
very small fold change from being judged as differentially
expressed due to an accidentally small residual SD. The
resulting p values were further adjusted using the BH FDR
algorithm [18]. Subsequently, differentially expressed genes
were sorted according to fold change (±1.5-fold or greater),
followed by secondary selection based on p-value and FDR
threshold (p < 0.05, FDR < 0.05, controlling the expected
FDR to no more than 5%).
Hierarchical clustering of differentially expressed genes
Hierarchical clustering was performed using the Agilent
GeneSpring GX software (version 12.0), and the results
were expressed as a dendrogram in which genes and sam-
ples with a similar expression pattern formed clusters.
Gene Ontology (GO) analysis
Gene Ontology (GO) analysis was applied to characterize
the primary functions of the differentially expressed genes
based on the key functional classification of NCBI [19].
Fisher’s exact test was used to classify the GO category. A
p-value was calculated for each GO term for all differen-
tially expressed genes and subsequently corrected by false-
discovery rate (FDR) [20]. A smaller FDR is associated
with a smaller error in judging the p-value. Next, enrich-
ment analysis was performed to find GO terms with more
specific functions. The enrichment Re was given by Re =
(nf/n)/(Nf/N), where nf is the number of differential genes
within the particular category, n is the total number of
genes within the same category, Nf is the number of differ-
entially expressed genes in the entire microarray, and N is
the total number of genes on the microarray.
Gene co-expression network
To identify modules of co-expressed genes [21], we built
the gene co-expression network according to the nor-
malized signal intensities of specific genes. We calcu-
lated the Pearson’s correlation for each pair of genes andchose those whose values fit the selection criterion to con-
struct the network [22]. Degree of centrality, defined as the
number of links between one node and the others, was
used as the simplest and most important measure of the
centrality of a gene within a network, which in turn deter-
mines that gene’s relative importance. In addition, the k-
core (from graph theory) was introduced to simplify the
graph-topology analysis for the purposes of locating the
core regulatory factors (genes) in the gene co-expression
network. The k-core of a gene co-expression network usu-
ally contains a cohesive group of genes [23-25]. A k-core
sub-network with a higher k-core level is considered to
have core status within a large-scale gene network.
Quantitative real-time PCR (qPCR)
Total RNA of each placental sample was prepared as de-
scribed in RNA preparation. Synthesis of cDNA was car-
ried out using Reverse Transcriptase M-MLV (RNase H-;
TaKaRa) and oligo-dT as the primer. QPCR was per-
formed on an Applied Biosystems 7500 Fast Real-Time
PCR System using Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA). Primer pairs
used were listed in Additional file 1: Table S1. Reactions
were performed in triplicate under standard thermocy-
cling conditions (one cycle of 94°C for 4 min, followed by
45 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for
40 s), and the mean threshold cycle number was used.
Histology and immunohistochemistry
Freshly isolated placental tissues were fixed with 4% PFA
overnight at 4°C, embedded in paraffin, sectioned at 4-μm
thickness, and followed by hematoxylin and eosin staining.
Immunohistochemical analyses were performed using
the LSAB kit (ZSGB-Bio, Beijing, China). Briefly, paraffin
sections were deparaffinized in xylene and rehydrated
sequentially in ethanol. The sections were microwaved
in EDTA buffer (pH 8.0) to retrieve antigens, incubated
in 3% H2O2 (10 min, room temperature) to inactivate
endogenous peroxidase. Sections were incubated with
blocking solution (15 min, 37°C), followed by incubation
in mouse anti-human CD45 antibody (1:200, 304002, Bio-
legend) diluted in blocking buffer (overnight, 4°C). The
samples were then incubated with biotinylated secondary
antibody (15 min, 37°C), followed by incubation with
streptavidin conjugated with HRP (15 min, 37°C) and
staining with DAB substrate. Nuclei were lightly counter-
stained with hematoxylin. Finally, slides were dehydrated
sequentially in ethanol, cleared with xylenes, and mounted
with neutral resin.
For immunofluorescence staining, tissue was fixed in 4%
PFA overnight at 4°C, immersed in sucrose solutions, em-
bedded in OCT (Tissue Tek) and sectioned. Frozen sec-
tions were incubated with 10% FBS (PBS) to block
nonspecific binding sites (1 h, RT) and further incubated
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700 conjugated, HIB19, 1:200, BD Pharmingen) or mouse
anti-human CD3 antibody (FITC conjugated, APA1/1,
1:200, BD Pharmingen) at 4°C overnight. Nuclei were
stained with DAPI.
The stained sections were imaged using an Olympus
BX51 microscope coupled with an Orca CCD camera
(Q-IMAGING).
Quantifications of blood vessels and immune cells
The HE staining image was used for blood vessel quanti-
fication. Ten sections of the terminal villi at the same
position in each placenta were examined and 5 random
fields in each slide were selected (50 fields total for eachFigure 2 Significantly enriched Gene Ontology (GO) terms associated
differentially expressed genes in ICP placentas were assessed by GO analys
(Intersection, A) and five significantly enriched GO terms in mild ICP only (
the GO category and the horizontal axis is the enrichment value of GO.placenta) to avoid areas of placental infarction and inter-
villous fibrin deposition, arterial vessels forming the pri-
mary stem and anchoring villi; and histological artifact.
The selected fields were then analyzed using ImageJ to
count the number of capillaries in each villus. Only ter-
minal villi showing outlines completely within the micro-
scopic field were analyzed. The number of capillaries per
villus was calculated by the total number of capillaries di-
vided by the number of terminal villi in 50 fields for each
placental sample.
For immune cell quantification, ten sections of the ter-
minal villi at the same position in each placenta were ex-
amined and the number of different immune cells in 5
random fields in each section were counted (50 fieldswith ICP pathogenesis. The primary functions of the sorted
is. Ten significantly enriched GO terms in both mild ICP and severe ICP
B) and severe ICP only (C) are shown respectively. The vertical axis is
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field was calculated for each placenta.
Statistical analysis
P values of qPCR results, immune cell quantification and
blood vessel quantification were calculated by analysis of
variance (ANOVA) with Dunnett post-tests. Significant
differences are indicated as: *, p < 0.05; **, p < 0.01. Each
experiment was repeated independently for three times.
Results and discussion
First we employed DNA microarray to identify differentially
expressed genes in mild ICP and severe ICP compared to
those in healthy pregnancies. Hierarchical clustering of
genes whose expression was altered by more than 1.5-fold
revealed that gene expression profiles of the two parallel
microarrays in each group were highly consistent, indicat-
ing the reproducibility of microarray data (Figure 1B).Figure 3 Gene-interaction network. Genes associated with the significan
which was built according to the relationships among genes, proteins, and
represent, respectively, genes differentially regulated in both mild ICP and
green represent genes that were differentially up-regulated or down-regula
each gene are shown in Additional file 3: Spreadsheet S1.Moreover, as can be observed from the heat map of clus-
tered genes, the three groups of pregnancies had distinctive
gene-expression profiles (Figure 1B).
Subsequently, we applied Gene Ontology (GO) ana-
lysis to assess the primary functions of the differentially
expressed genes [19] (Figure 2A–C). There was exten-
sive overlap between the GO terms of mild ICP and se-
vere ICP, indicating a strong correlation between mild
ICP and severe ICP (Figure 2A). In addition, it is worth-
while to note that the GO terms specifically enriched in
severe ICP were mainly related to immune-related sig-
naling pathways (Figure 2C).
To further characterize the core regulatory genes in-
volved in the pathogenesis of ICP, genes associated with the
significantly enriched GO terms were used to construct
gene-interaction and gene co-expression networks [21,26]
(Figure 3 and Additional file 2: Figure S1). Detailed gene-
gene relationships with the degree of each gene from gene-tly enriched GO terms were analyzed by gene-interaction network,
compounds in the KEGG database. Circles, squares, and triangles
severe ICP (Intersection), mild ICP only, and severe ICP only. Red and
ted, respectively. Detailed gene-gene relationships with the degree of
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shown in Additional file 3: Spreadsheets S1 and Additional
file 4: Spreadsheets S2, respectively. These two networks
identified the following 19 core regulatory genes: CCL3,
CCL25, CXCL6, CXCL14, CCR4, CCR6, CCR9 and IL-7R in-
volved in immune response; VEGFC, FZD4, FGF9, FGF18,
ITGB3, and FLT1 involved in VEGF signaling pathway; and
GNAS, GNA12, GNA14, EGF, and EGFR involved in G-
protein-coupled receptor (GPCR) signaling.
Next we used qPCR to confirm the expression patterns
of the identified 19 core regulatory genes in 30 individuals
in all three groups (Additional file 1: Table S1). 14 of 19
detected genes exhibited expression patterns consistent
with those from the microarray data, confirming the ac-
curacy of the microarray data (Figure 4).
Despite decades of research, pregnancy is characterized
by quite an unusual number of rather frequent conditions
with unknown etiology. Although previous studies have
provided some information on the altered gene expression
profile in ICP placentas [14,27], they did not discriminate
between patients with mild ICP and severe ICP. In this
study, to further reveal the influence of different bile acidFigure 4 Validation of the identified core regulatory genes associated
placental tissues from healthy group, mild ICP, and severe ICP (10 pregnan
shown: Genes involved in (A) immune response, (B) VEGF signaling and (C
each target gene was normalized to GAPDH, and expression levels in the h
triplicate, and data are presented as mean ± s.d. (n = 10). *p < 0.05; **p < 0.0
Additional file 1: Table S1.concentration in the pathogenesis of ICP, we sub-grouped
the ICP patients into mild and severe ICP according to
their serum bile acid level. In addition, as ICP women de-
livered at earlier gestational stage than healthy pregnant
women (Figure 1A), it is possible that different gestational
ages of healthy and ICP groups might affect the mRNA
expression of placentas. Nevertheless, we were not able to
collect placentas from healthy women and women with
ICP of the same gestational age in clinical cases, which is a
common problem encountered by other studies on the
placental gene expression profiles of healthy pregnant
women and women with ICP [14,27].
Like Gleicher has pointed out in a number of publica-
tions, these unexplained conditions of pregnancy exhibit
characteristics similar to immunological conditions ob-
served in organ transplant rejection [28] and/or graft versus
host disease (GVHD) [29], therefore ICP may represent the
complications of normal tolerance of the fetal semi-
allograft by the maternal immune system [30]. Herein, our
microarray results revealed that genes associated with im-
mune response, CXCL6, CXCL14 and IL-7R were up-
regulated in mild ICP and further up-regulated in severewith ICP pathogenesis by qPCR. Genes with expression patterns in
cies per group) consistent with those in the microarray data are
) G-protein-coupled receptor (GPCR) signaling. Relative expression of
ealthy group were defined as 1. All reactions were performed in
1; ***p < 0.001; NS, not significant. Primer pairs used were listed in
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vere ICP, which suggest that abnormal immune response in
patients’ placentas might be positively correlated to the se-
verity of ICP. To explore this implication, we compared the
infiltration of CD45 positive leukocytes in placentas from
healthy pregnant women and patient with mild or severe
ICP. Few leukocytes were present in normal placentas,
whereas placentas from mild ICP exhibited more leuko-
cytes aggregation, and placentas from severe ICP displayed
massive leukocytes infiltration (Figure 5A). These results
are consistent with the gradually elevated expression levels
of immune-related genes in mild and severe ICP placentas,
and suggest that ICP is associated with immune activation.
To further determine which types of immune cells were re-
cruited into placenta in ICP, we stained CD3 positive T cells
and CD19 positive B cells in placentas. Compared with nor-
mal placentas, placentas from mild ICP showed signifi-
cantly increased infiltration of both T cells and B cells, and
the T/B cells infiltration was further augmented in placentaFigure 5 Immune cell infiltration in placental tissues from healthy gro
immunohistochemistry staining for the leukocyte marker CD45 in placenta
per group). Brown staining (arrows) indicates reactivity. Scale bars represen
positive) and B cell (CD19 positive) in placental tissues from healthy group,
presented as mean ± s.d. (n = 10). **p < 0.01; ***p < 0.001.from patient with severe ICP (Figure 5B). Taken together,
our study suggests that ICP is an immunological/inflamma-
tory condition and provides an evidence to support such an
interpretation that ICP might be either an allograft rejection
mechanism or, more likely, a counterpart to GVHD in
organ transplantation.
Development of a normally functioning placental vascu-
lar network to support increasing oxygen and metabolic
demands of the growing fetus is necessary for a successful
pregnancy. This requires substantial coordination among
different vascular endothelial cell-specific growth factors
and cell types and is exquisitely dependent on signals ex-
changed between these cells [31]. As revealed by this study,
ICP was accompanied by aggregated immune cell infiltra-
tion and gene expression levels of FGF9 and ITGB3 were
significantly down-regulated in ICP placentas (Figure 5A
and Figure 4B). Given the fact that immune cells are able to
intimately regulate vessel formation and function [32] and
considering the essential role of FGF9 and integrin β3 inup, mild ICP, and severe ICP. (A) Representative images of
l tissues from healthy group, mild ICP, and severe ICP (10 pregnancies
t 100 μm. (B) Quantification of leukocytes (CD45 positive), T cell (CD3
mild ICP, and severe ICP (10 pregnancies per group). Data are
Figure 6 Histological staining of placental tissues from healthy group, mild ICP, and severe ICP. (A) Representative hematoxylin and eosin
staining of placental tissues from three groups of pregnancies (10 pregnancies per group). Scale bar represents 200 μm. (B) Quantification of
capillaries per villus of placental tissues from three groups of pregnancies (10 pregnancies per group). Data are presented as mean ± s.d. (n = 10).
*p < 0.05; **p < 0.01.
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that formation and maturation of placental blood vessels
might be impaired under conditions of ICP. To test this hy-
pothesis, we subjected placental tissues from healthy and
ICP pregnancies to hematoxylin and eosin staining to
visualize the vascular structure. Normal placentas exhibited
well-organized vascular structure consisting of large vessels
(Figure 6A). By contrast, placentas from mild or severe ICP
exhibited fewer and smaller blood vessels in each villus
(Figure 6A,B), indicating disturbed placental vascular for-
mation and deficient vascular maturation. Interestingly, pla-
cental gene expression of FZD4, which plays an essential
role in vascular development [35], was increased in mild
ICP but not in severe ICP (Figure 4B). Since previous stud-
ies have shown that FZD4 expression can be induced by
hypoxia [35], it is speculative that up-regulation of FZD4 in
mild ICP may serve as a mechanism to compensate for
fluctuations of oxygen and hypoxia that result from lack of
vessel formation and blood supply. However, this type of
compensation does not exist under condition of severe
ICP, which may explain, albeit partially, observations of di-
lated maternal vascular lacunae in severe ICP placentas
(Figure 6A). Moreover, it is worthwhile to note that, gene
expression of VEGFC was up-regulated in both mild ICP
and severe ICP (Figure 4B). Given the function of VEGFC
in blood vessel formation [36,37] and the fact that high
levels of bile acids exert a constrictive effect on isolated
human placental chorionic veins [38], it is tempting to
speculate that VEGFC expression was up-regulated as a
compensation for hypoxia induced by elevated concentra-
tions of bile acids in ICP placentas.
Additionally, in ICP placentas, we observed differential
regulation of critical regulatory genes involved in GPCR
signaling, including EGF, EGFR, and genes encoding G-
protein subunits such as GNA14 (Figure 4C). Because
GPCR signaling plays important roles in immune response,
this finding implies a potential link between GPCR signal-
ing and the abnormal immune activation in placentas of
ICP patients.Conclusions
In conclusion, our study provides a system-level insight into
the placental gene-expression profiles of women with mild
or severe ICP, and reveals multiple molecular pathways in
immune response and blood vessel formation that might
contribute to ICP pathogenesis. These findings should fa-
cilitate elucidation of the mechanisms of ICP development
and may suggest therapeutic strategies for management of
this disease.
Additional files
Additional file 1: Table S1. Primer pairs used for quantitative real-time
PCR.
Additional file 2: Figure S1. Gene co-expression network. Genes
associated with the significantly enriched GO terms were analyzed by
gene co-expression network using k-core algorithm. Node size
represents the strengths of relationships among nodes, and edges
between two nodes represent interactions between genes. Genes that
connect more edges (i.e., to more genes) play more central roles within
the network. Circles, squares, and triangles represent, respectively, genes
differentially regulated in both mild ICP and severe ICP (Intersection),
mild ICP only, and severe ICP only. Red and green represent genes that
were differentially up-regulated or down-regulated, respectively.
Detailed gene-gene relationships with degree and k-core of each gene
are shown in Additional file 3: Spreadsheet S2.
Additional file 3: Spreadsheet S1. The detailed gene-gene
relationships in the gene-interaction network.
Additional file 4: Spreadsheet S2. The detailed gene-gene
relationships from the gene co-expression network.
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